Afstyla market forecast points to growth through 2035

The Business Research Company says the Afstyla market is gaining traction as hemophilia A diagnoses rise and more patients move toward recombinant factor VIII therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Afstyla sits in a growing hemophilia A treatment market where higher diagnosis rates, broader access to care and newer dosing approaches can change how patients prevent and manage bleeding. - The market outlook points to demand from both newly diagnosed patients and broader use of prophylactic, home-based treatment.

What happened: - The Business Research Company published its Afstyla Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says Afstyla is used to treat hemophilia A by replacing missing clotting factor VIII. - Afstyla is administered intravenously after preparation. - The report says North America held the largest Afstyla market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - More information is available in the full report and a free sample.

The details: - Historic growth was tied to improved hemophilia A diagnosis, wider use of factor replacement therapies, better survival rates, access to recombinant clotting factors and growth in specialized care centers. - Forecast growth is expected to come from more prophylactic treatment use, rising pediatric diagnoses, recombinant manufacturing innovation, broader homecare adoption and expansion into emerging markets. - The report flags three major trends: greater reliance on recombinant factor VIII therapies, stronger emphasis on bleed prevention and more home-based infusion treatment. - Flexible dosing options are expected to improve treatment compliance. - A rise in hemophilia A cases is a major market driver because the genetic disorder causes a deficiency of clotting factor VIII and leads to prolonged bleeding. - The report links rising diagnoses to better detection, reporting, awareness and genetic and environmental factors. - The report says Afstyla can support adherence, quality of life and cost-effectiveness because it is a long-acting treatment. - In April 2024, the World Federation of Hemophilia reported 7,054 new bleeding disorder cases across PACT countries in 2023, including 5,188 hemophilia cases. - The World Federation of Hemophilia expects diagnosed patients to reach 18,832 by 2025. - Rising healthcare spending is another growth factor because larger budgets can expand access to advanced hemophilia therapies. - A UK government report from May 2024 showed total healthcare expenditure rose 5.6% from 2022 to 2023. - Long-term health and social care spending also rose in that period. - Growing use of personalized medicine is supporting demand for tailored hemophilia treatments. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The report frames Afstyla as part of a broader shift toward more individualized hemophilia care rather than one-size-fits-all treatment. - The fastest growth in Asia-Pacific suggests expanding access and diagnosis outside the most mature markets may be a bigger driver than new demand in North America. - The emphasis on homecare and prophylaxis points to competition around convenience, adherence and long-term disease control, not just drug availability.

What's next: - The report expects adoption to keep rising as pediatric diagnoses increase and more patients move into preventive treatment pathways. - Emerging-market expansion and recombinant manufacturing improvements could widen the addressable market through 2035. - The company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and trend analysis. - The Business Research Company lists contact details for expert inquiries and provides social media links in the release.